Introduction
Angiogenesis, the establishment of a neovascular blood supply derived from pre-existing blood vessels, mainly depends on the proper activation, proliferation, adhesion, migration and maturation of endothelial cells (ECs) (Figure 1 ) (Griffioen and Molema, 2000; Tomanek and Schatteman, 2000; Ellis et al., 2001) . Interestingly, the process of tumorigenesis and metastasis, like that of angiogenesis, is particularly sensitive to a loss of control growth, an imbalanced regulation of proteolysis and an imbalanced regulation of cell motility ( Figure 1) (Moses, 1997) . These processes are driven by angiogenic stimuli and proteolytic enzymes that cleave extracellular matrix (ECM) components (Moses, 1997) . Proteolysis of the ECM allows cell migration and may release stored angiogenic molecules (Moses, 1997) . In postnatal life, angiogenesis is physiological (ovarian and menstrual cycles and pregnancy, wound healing) or associated with a pathological condition (Tomanek and Schatteman, 2000; Ellis et al., 2001) . Angiogenesis is low in diseases such as tissue damage following ischemic tissue or cardiac failure (Griffioen and Molema, 2000) . On the contrary, excessive angiogenesis is part of the pathology and includes inflammatory (rheumatoid arthritis, diabetic retinopathy and nephropathy) and cardiovascular (atherosclerosis) diseases, and cancer (solid and hematologic tumors) (Griffioen and Molema, 2000) .
Apart from the matrix metalloproteinases (MMPs) and the plasminogen activator-plasmin system implicated in angiogenesis due to their ability to cleave ECM (Egeblad and Werb, 2002) , it emerges that transmembrane proteases (TPs) could also participate in angiogenic processes. TPs are widely distributed, outside and inside the vascular system (Goding, 2000; Primakoff and Myles, 2000; Antczak et al., 2001a, b; Black, 2002; Seiki, 2002; Seiki and Yana, 2003) . They are expressed by forming blood vessels, leukocytes and a large number of tumor cells. This article focuses on the TPs recently implicated in processes related to angiogenesis, that is, MT1-MMP/MMP-14, ADAM-17/TACE and three ectopeptidases, angiotensin-converting enzyme/ACE/ CD143, aminopeptidase N/APN/CD13 and dipeptidyl peptidase IV/DPPIV/CD26. Current knowledge of these TPs is summarized in this article, and salient advances in what is currently known of their related-angiogenic activities are discussed.
Structure and enzymatic activity of TPs

ADAM-17/TACE
The ADAMs belong to the metzincin superfamily of Zndependent metalloproteinases (Primakoff and Myles, 2000; Black, 2002) . They have also been referred to as MDCs, which stands for metalloproteinase disintegrin with cysteine-rich domains. Initial observations indicated that membrane pro-TNF-a was released through the action of a TNF-a convertase enzyme (TACE) (Cerretti, 1999; Black, 2002) . TACE was subsequently cloned and found to be identical to ADAM-17 (Cerretti, 1999) . ADAM-17/TACE contains the distinctive zincbinding consensus HEXXH (His-Glu-Xaa-Xaa-His) sequence in the catalytic domain, a disintegrin-cysteine-rich sequence and a prodomain containing a cysteine that interacts with the active-site zinc of the catalytic domain (Figure 2 ) (Primakoff and Myles, 2000; Black, 2002) . ADAM-17/TACE becomes an active enzyme following the cleavage of the prodomain by a furin-type protease (Primakoff and Myles, 2000) . Similar to other ADAMs, the disintegrin domain in TACE could have an adhesion function by interacting with integrins (Black, 2002) .
ADAM-17/TACE is involved in the proteolysis of collagen IV of the ECM and also in the release from the cell surface of several integral proteins (Table 1) (Black, 2002) . These include inflammatory cytokines such as proTNF-a, proTGF-a and (b-amyloid-precursor-protein (APP), cytokine receptors (p75 TNF-a receptor, M-CSF receptor and CD30 a member of TNF receptor family), the cell adhesion molecules L-selectin and collagen XVII and a major component of the glycocalyx MUC1 ( Rovida et al., 2001; Slack et al., 2001; Black, 2002; Franzke et al., 2002; Thathiah et al., 2003) . TIMP-3, the endogenous inhibitor of MMPs, inhibits ADAM-17 (Black, 2002) .
MT1-MMP/MMP-14
The secreted MMPs are multidomain zinc-dependent endopeptidases that share a basic structural organization comprising a prometallo domain, a metallodomain and a hemopexin-like domain (Murphy and Gavrilovic, 1999) . The prodomain maintains the metalloprotease domain in an inactive state until it is cleaved off. Over recent years, the MMP family has been expanded to include a new subfamily of membranetethered MMPs known as membrane-type MMPs (MT-MMP) (Figure 2) (Seiki, 2002) . MTl-MMP contains a membrane-spanning sequence in the fourth and last pexin-like repeat of the carboxy-terminal domain (Seiki, 2002) .
The contribution of MTl-MMP is the destruction of a variety of molecules constituting the ECM, including fibrillar collagens (type I, II and III), fibronectin, laminin-1 and -5, vitronectin and aggregan (Table 1) (Ohuchi et al., 1997; Seiki and Yana, 2003) . MTl-MMP activates the latent form of secreted proMMP-2 (progelatinase A) (Schwartz et al., 1998; Nagase and Woessner Jr, 1999; Hernandez-Barrantes et al., 2000) , and the hydrolytic activity on type I collagen is synergistically increased with MMP-2 (Table 1) (Ohuchi et al., 1997) . Similarly, activation of proMMP-13 (procollagenase-3) by MTl-MMP is enhanced in the presence of proMMP-2 (Knauper et al., 1996) . In addition, MTl-MMP can degrade fibrinogen and Factor XII (Table 1) (Tschesche et al., 2000) . Finally, MTl-MMP processes membrane CD44 (a multifunctional adhesion molecule) (Kajita et al., 2001 ) and undergoes autocatalytic processing on the cell surface, releasing its entire catalytic domain (Toth et al., 2002) .
The natural inhibitors of MMPs are TIMPs (tissue inhibitors of metalloproteases) (Murphy and Gavrilovic, 1999; Marguet et al., 2000) . TIMP-2 interacts with both MTl-MMP (in its catalytic domain) and soluble proMMP-2 (in its hemopexin-like domain) (HernandezBarrantes et al., 2000) leading to the formation of a ternary complex which clusters proMMP-2 at the cell surface near a TIMP-free active MT1-MMP, which in turn initiates activation of proMMP-2 Hernandez-Barrantes et al., 2000) . The membrane-anchored MMP inhibitor RECK initially described as a negative regulator of MMP-9 and an inhibitor of tumor invasion is also capable of inhibiting both MMP-2 and MT1-MMP (Oh et al., 2001) .
DPPIV, APN and ACE
Until now, three ectopeptidases have been implicated in events related to angiogenesis. They are represented by the serine peptidase DPPIV/CD26 characterized by the catalytic amino-acid triad His, Asp and Ser, and the two metallo-dependent peptidases APN/CD13 and ACE/CD143 (Figure 2 ) Riemann et al., 1999; Goding, 2000; Antczak et al., 2001a, b) . They are anchored in the plasma membrane either by the N-terminus (type I, ACE) or the C-terminus (type II, APN, DPPIV) facing extracellularly. With regard to DPPIV, a cysteine-rich domain interacts with collagen and fibronectin of the ECM (Figure 2 ) Antczak et al., 2001a) . Adenosine deaminase, which catalyses the irreversible deamination of (2 0 deoxy)adenosine to (2 0 deoxy)inosine is also capable of binding the cysteine-rich domain of DPPIV . Moreover, the carbohydrate-binding region [(QxW)3] in DPPIV, in concert with the integrin a2bb3, is a receptor for plasminogen (Gonzalez-Gronow et al., 2001) . No endogenous inhibitors of ectopeptidases have so far been characterized.
As shown in Table 1 , ectopeptidases have the capacity to process various bioactive peptides implicated in vascular permeability (neuropeptides such as bradykinin, angiotensins, substance P, vasostatin, neuropeptide Y) (Zhang et al., 1999; Antczak et al., 2001a, b) . For example, ACE and APN hydrolyse angiotensin I to generate the vasoconstrictor angiotensin II, while ACE inactivates the vasodilatator bradykinin. Truncation by DPPIV of neuropeptide Y and peptide YY generates a shift in their receptor selectivity and alters their biological specificity from vasoconstriction to growth factor activity . Ectopeptidases also play an important role in the upregulation or downregulation of the activities of several chemotactic peptides (substance P, f-MLP, MCP-1, MIP-1, RANTES, SDF-1, eotaxin, MDC, LIF, LD78b, IP-10 and I-TAC) (Table 1) Proost et al., 2000 Proost et al., , 2001 Antczak et al., 2001a, b; Ludwig et al., 2002) . Importantly, some substrates of the ectopeptidases exhibit proangiogenic (angiotensin II, bradykinin, neuropeptide Y) or angiostatic (vasostatin, IP-10, I-TAC) activity (Table 1 ) (Zukowska-Grojec et al., 1998; Griffioen and Molema, 2000; Knox et al., 2001; Silvestre et al., 2001; Yoshiji et al., 2001) .
Normal distribution and correlation with human pathology
TPs are widely distributed outside the hematopoietic system (Table 1) and, in the hematopoietic compartment, are not confined to a particular lineage (Table 1) (Yamamoto et al., 1999; Antczak et al., 2001a; Black, 2002; Bueno et al., 2002; Seiki, 2002) . Soluble forms of MT1-MMP, ACE, DPPIV and APN are detectable in biological fluids (plasma, urine, synovial fluid) (Antczak et al., 2001b; Seiki, 2002; Kawai et al., 2003) . TPs have been cloned and are localized at distinct chromosomal loci (Cambien and Soubrier, 1995; Alhenc-Gelas et al., 1997; Mattei et al., 1997; Cerretti, 1999; Antczak et al., 2001a) . A polymorphism in the ACE gene exists, consisting of the insertion (I) or deletion (D) of a 287 bp DNA fragment in intron 16, which accounts for 20% of the variance in ACE expression or activity in blood and tissues among individuals (Cambien and Soubrier, 1995; Danilov et al., 1996) . Striking changes in the expression of membrane and/or soluble forms of TPs are observed in various human diseases. A brief summary is presented here (Table 1) .
Cancer
Alterations of the TPs described herein are detected in solid and hematologic tumors (Table 1) (Ueno et al., 1997; Afzal et al., 1998; Harada et al., 1998; Kitagawa et al., 1998; Curran and Murray, 1999; Ellerbrock and Stack, 1999; Ishigaki et al., 1999; Brinckerhoff et al., 2000; Ellenrieder et al., 2000; Neal et al., 2000; Antczak et al., 2001a, b; Fillmore et al., 2001; Kerkela et al., 2001; Soderstrom et al., 2001; Hashida et al., 2002; Mishima et al., 2002; Seiki and Yana, 2003) . In some cases, malignancy is associated with a marked increase in TP expression, whereas in others it is associated with downregulation. Often, dysregulation of TPs in tumors has been linked to tumor initiation, invasion and metastasis. However, the unique example of a causal relationship between TP expression and pathology is seen in human melanocytes where the loss of DPPIV is invariably associated with malignant transformation (Wesley et al., 1999) .
Cardiovascular diseases
Overexpression of both membrane and/or soluble forms of MT1-MMP, DPPIV and ACE is correlated to cardiovascular diseases (myocardial infarction, stroke, hypertension) and their complications (atherosclerosis, diabetic nephropathy and retinopathy, vasculitides) (Table 1) (Cambien et al., 1992; Ishii et al., 1994; Vranes et al., 1995; Rajavashisth et al., 1999; Antczak et al., 2001b) . TACE and DPPIV are overexpressed in myocarditis (Satoh et al., 2000; Schonermarck et al., 2000) . Endothelial ACE and macrophage MT1-MMP are overexpressed in advanced stages of atherosclerosis (Rajavashisth et al., 1999; Phillips and Kagiyama, 2002) . With regard to ACE, the DD genotype inducing high expression of plasma ACE is associated with myocardial infarction, stroke and diabetic nephropathy (Samani et al., 1996; Antczak et al., 2001b; Hadjadj et al., 2001) . Hypertensive patients with elevated pulmonary artery pressure exhibit significantly increased levels of plasma DPPIV (Table 1) (Papies et al., 1991) .
Other diseases
Various reports detail the dysregulated expression of TPs in infection (HIV, HCV), inflammation (multiple sclerosis, rheumatoid arthritis, diabetes, leprosy, sarcoidosis), Alzheimer's disease and other pathological conditions (Patel et al., 1998; Karkkainen et al., 2000; Pap et al., 2000; Yamanaka et al., 2000; Antczak et al., 2001a, b; Honda et al., 2001; Ohta et al., 2001; Skopinski et al., 2001; Skovronsky et al., 2001; Hooper and Turner, 2002; Seifert et al., 2002) . With regard to its upregulation in rheumatoid arthritis, TACE of macrophages is suggested to play a role in the production of the proangiogenic molecule TNF-a that is not detected in normal cartilage (Ohta et al., 2001) . Increased expression of DPPIV of T cells in leprosy and other granulomatous diseases correlates with the production of IFN-g (Scheel-Toellner et al., 1995) .
In Vivo investigations of TPs
Inhibition of TP activity in animal models
Numerous data documenting the involvement of TPs in pathophysiological events have come from studies that blocked TP activity in animal models (Table 2 ). In mice, rat and hamster models, inhibitors of ACE (omapatrilat, fasidotril, Z13752A, SA7060) block both angiotensin II release and bradykinin inactivation thus decreasing the mean blood pressure and augmenting cardiac output (Burrell et al., 2000; Kuro et al., 2000; Laurent et al., 2000; Antczak et al., 2001b) .
In the mouse brain, APN inhibition by PC18 increases the half-life of angiotensin III, resulting in enhanced vasopressin release (Zini et al., 1996) . In rats, infusion of the inhibitor of APN, amastatin, prevents degradation of angiotensins and is associated with blood pressure decrease (Ahmad and Ward, 1990; Wright et al., 1991) .
DPPIV inhibition (by Pro-Pro-Diphenyl-Phosphonate) in a rat model is associated with delayed acute rejection and a block of the increase in serum DPPIV normally associated with cardiac allotransplantation . Treated animals lack the allospecific IgM response and had greatly decreased serum IgG titers, suggesting that the activity of DPPIV interferes with the early steps in the humoral response to alloantigen after organ transplantation Korom et al., 1999) . More recently, it has been shown that inhibition of DPPIV improves glucose tolerance in diabetic animals (mice, rats and pigs) through augmentation of endogenous levels of intact glucagon-like peptide 1 (GLP-1, a DPPIV substrate) which enhances glucose-stimulated insulin secretion (Antczak et al., 2001b) . With regard to DPPIV and autoimmunity, inhibition of DPPIV by Lys[ZNO2)]-pyrrolidide in murine experimental autoimmune encephalomyelitis (EAE) leads to decreased and delayed clinical and neuropathological signs of EAE possibly through a mechanism that includes an active TGF-bl-mediated anti-inflammatory effect at the site of pathology (Prud'homme and Piccirillo, 2000) . In experimental rat and mouse models of colitis and arthritis, where TNF-a plays a role, the use of TACE inhibitors (BB1101 and GW3333) leads to a decrease of inflammation associated with the inhibition of TNF-a release (Colon et al., 2001; Conway et al., 2001; Newton et al., 2001; Xue et al., 2001; Doggrell, 2002) . Two newly designed inhibitors of TACE (PKF242-484 and PKF-241-466) have beneficial effects in murine models of acute lung inflammation (asthma and chronic pulmonary disease) and other inflammatory diseases Trifilieff et al., 2002) .
Knockout mice
Targeted mutations in mice of the genes encoding ACE, DPPIV, TACE and MT1-MMP confirm their involvement in pathophysiology (Table 2) .
Mice lacking ACE have reduced blood pressure, impaired male fertility and kidney defects characterized by arterial thickening and infiltration of inflammatory cells (Krege et al., 1995; Bernstein, 1998; Hagaman et al., 1998) . Targeted inactivation of the DPPIV gene yields healthy mice that have increased levels of GLP-1 and insulin (Marguet et al., 2000) confirming that DPPIV participates in blood glucose regulation by partially controlling the activity of GLP-1.
The majority of TACE-deficient mice died between embryonic day 17.5 and the first day after birth (Black, 2002) . In TACE-deficient mouse embryos, shedding of collagen XVII and TNF-a is significantly reduced in TACE-deficient keratinocytes (Franzke et al., 2002) . Surviving mice display various degrees of eye degeneration with apparent corneal inflammation, as well as hair and skin defects (Black, 2002) . This set of characteristics resemble the phenotype of mice lacking TGF-a which is involved in normal development (Black, 2002) . In addition, TACE-deficient mice exhibit a marked pulmonary hypoplasia (Zhao et al., 2001 ).
MT1-MMP-deficient mice display severe skeletal defects that lead to the development of craniofacial dysmorphism, arthritis, osteopenia, dwarfism and fibrosis of soft tissues and premature death (Holmbeck et al., 1999) . Other tissues in these null mice, however, develop relatively normally (Holmbeck et al., 1999) . The skeletal defects are in part due to the lack of a collagenolytic activity and decreased vascular invasion of calcified cartilage (Holmbeck et al., 1999) . Moreover, null mice do not have an angiogenic response to implanted FGF-2 in in vivo corneal assay (Zhou et al., 2000) . Reduced activation of proMMP-2 is observed in various tissues of MT1-MMP null mice (Zhou et al., 2000) .
TP inhibition and human therapy
Three inhibitors of ACE, omapatrilat, lisinopril and fasidotril, effectively lower blood pressure in patients with chronic heart failure, diabetic nephropathy and post-transplantation erythrocytosis (Burnett, 1999; Glicklich et al., 1999; Asher and Naftilan, 2000 (Table 2) . Moreover, it was recently reported that cancer is decreased in patients receiving an ACE inhibitor (Lever et al., 1998) . ACE inhibitor (quinapril) therapy reduces atherosclerosis induced by Marek's disease virus infection and cholesterol diet (Lucas et al., 1998) . The orally available DPPIV inhibitor P32/98 (Ile-thiazolidide based) has passed preclinical development stages in animal models, and is currently being tested in Phase I trials for diabetes (Antczak et al., 2001b) . Inhibitors of TACE and MT1-MMP are currently being studied in drug discovery projects for the treatment of arthritis and congestive heart failure, respectively (Spinale et al., 2000; Doggrell, 2002; Moss and Lambert, 2002) .
TPs in cell growth and invasion
The requirement for TPs in cell growth and motility has mostly been demonstrated with in vitro and in vivo studies in which TP activity or expression is blocked respectively by specific inhibitors, neutralizing antibodies or antisense oligonucleotides (Table 3) .
TPs regulate cell proliferation
Various studies indicate that the interaction of MTl-MMP, APN, DPPIV and ACE with their inhibitors or specific antibodies arrests cell proliferation of various cell types in vitro (keratinocytes, epithelial, endothelial and leukocytes) (Comte et al., 1997; Antczak et al., 2001a, b; Lohn et al., 2002; Mishima et al., 2002; Yoshiji et al., 2002a) and tumor xenografts (Pasqualini et al., 2000) . Moreover, abrogation of TACE by oligosense nucleotide strategy or inhibition of its activity is associated with inhibition of embryonic mouse lung morphogenesis in culture (Zhao et al., 2001) . A question central to TP inhibition studies is how cell growth can be turned off. Recent studies suggest that inhibitors of TPs could interfere with intracellular signalling. MT1-MMP-, APN-, DPPIV-mediated signal transduction involves the MAP kinase signalling pathway Santos et al., 2000; Annabi et al., 2001; Bauvois, 2001; Antczak et al., 2001a, b) . The cytoplasmic tail of ADAM-17 contains SH3 consensus sequences suggesting a role in signal transduction (Yamamoto et al., 1999; Black, 2002) .
TPs regulate the release of angiogenic molecules
Cell growth arrest correlates with alterated secretion of (pro/anti-) inflammatory cytokines and other hemoregulators (Table 3) . APN inhibition increases the levels of IL-8 secreted by endothelial cells (Mishima et al., 2002) , whereas it decreases IL-6 production by monocytes (Chomarat et al., 1995) . DPPIV inhibition leads to an increase in the secretion of latent transforming growth factor-b1 (TGF-b1) and suppression of IL-2, -10, -12 and IFN-g by stimulated T cells . Moreover, DPPIV antibodies, by blocking the interaction between DPPIV and plasminogen on the surface of human prostate tumor cells, inhibit production of proMMP-9 (Gonzalez- Gronow et al., 2001) . ACE inhibitors suppress the release of TNF-a, IL-1, IL-12 and tissue factor (TF) by leukocytes (Constantinescu et al., 1998; Napoleone et al., 2000) . With regard to cell surface cytokine shedding, inhibitors of TACE block the release of the soluble forms of TNF-a and TGF-a (Black, 2002; Moss and Lambert, 2002) .
All these released inflammatory factors stand out as associated factors with various aspects of angiogenesis (Sunderkotter et al., 1994; Beckner, 1999; Tomanek and Schatteman, 2000; Crowther et al., 2001; Kuroi and Toi, 2001) . MMP-9, IL-1, IL-6, IL-8, TNF-a and TGF-a are proangiogenic factors produced by tumor cells and activated macrophages (Sunderkotter et al., 1994; Beckner, 1999; Crowther et al., 2001) . IL-1, IL-6, IL-8, TGF-a, TGF-b1, TNF-a and TF are implicated in proliferation, differentiation and motility of human vascular endothelial cells (Sunderkotter et al., 1994; Beckner, 1999; Crowther et al., 2001) . TNF-a, by inducing production of proteinases (MMP-9 and u-PA) and proteinase inhibitor (PA-I) by endothelial cells, aids angiogenesis through ECM degradation, which in turn facilitates endothelial cell migration (Beckner, 1999) . Moreover, TGF-b1 can induce up or down regulation of MMP activity by infiltrated macrophages (Beckner, 1999; Meisser et al., 1999; Feinberg et al., 2000; Chang and Werb, 2001 ). In contrast, inhibitory effects of IFNg, TGF-b, IL-10 and IL-12 on angiogenic activities have been reported (Hiscox and Jiang, 1997; Beckner, 1999; Moehler et al., 2001) . Therefore, it appears that a relationship between TP activity and angiogenesis exists.
TPs are involved in cell motility
Cell motility plays a central role in development, wound healing and immune response, and also in the development of many pathological conditions including inflammatory disorders, atherosclerosis and metastatic tumor spread. TPs influence cell migration and invasion through different mechanisms including processing of chemokines, degradation of ECM or shedding of cell adhesion molecules (Table 3) (Fujii et al., 1995; Antczak et al., 2001a; Ishii et al., 2001; Black, 2002; Hashida et al., 2002; Seiki, 2002) .
Processing of chemokines Chemokines are locally produced by injured or infected tissues (Opdenakker and Van Damme, 2002) . They are involved in cancer invasion, multiple sclerosis, atherosclerosis, arthritis, wound healing and ischemia, and therefore play a critical role in the regulation of angiogenesis (Opdenakker and Van Damme, 2002; Bernardini et al., 2003) . By acting through functional chemokine receptors (Opdenakker and Van Damme, 2002; Bernardini et al., 2003) , chemokines selectively induce migration and stimulate cell growth of leukocytes, tumor cells and endothelial cells (Opdenakker and Van Damme, 2002; Bernardini et al., 2003) . The ectopeptidases APN and DPPIV, by hydrolysing chemokines, influence cell motility. APN inhibitors (actinonin, bestatin) are able to enhance the chemotactic response of human neutrophils toward MCP-1 and MIP-a (Tables 1 and 3) Goding, 2000; Antczak et al., 2001a, b) . Following truncation of their N-terminal region by DPPIV, processed RANTES, SDF-la, MDC, eotaxin and I-TAC lose their chemotactic potency toward monocytes, eosinophils, lymphocytes and dendritic cells Proost et al., 2000 Proost et al., , 2001 . The angiostatic chemokines IP-10 and Mig, both cleaved by DPPIV, have reduced chemotactic activity, but retain their ability to inhibit angiogenesis (Proost et al., 2001) . In contrast, DPPIV converts the chemokine LD78b, an inhibitor of macrophage tropic human immunodeficiency virus-1, into a most efficient monocyte chemoattractant (Proost et al., 2000) . A large body of evidence shows that following chemokine alterations, signalling properties through RANTES, eotaxin and SDF-la receptors (CCR1, CCR3, CXCR4) are impaired (De Meester et al., 1999) . Degradation of ECM As a consequence of localized ECM degradation, cells can detach and migrate. MTl-MMP, TACE, APN and DPPIV have been implicated in cell invasion through their abilities to degrade the ECM (Saiki et al., 1993) . MT1-MMP and TACE are directly involved in the degradation of collagens abundant in inflamed and tumoral tissues (Tables 1 and 3 ) (Primakoff and Myles, 2000; Black, 2002; Seiki, 2002) . MTl-MMP is indirectly implicated in collagen breakdown by activating proMMP-2 and proMMP-13 (Seiki, 2002) . Similarly, APN could be indirectly involved in collagen degradation by activating proMMP-9 to achieve tumor cell invasion (Saiki et al., 1993; Fujii et al., 1995) . In the rat model, DPPIV, which normally cleaves peptide bonds after penultimate proline, is suggested to exhibit endopeptidase activity toward denatured collagen (Bermpohl et al., 1998) . Moreover, and as evoked above, the interaction between DPPIV and plasminogen on the cell surface regulates the expression and release of proMMP-9 (Table 3 ) (Gonzalez-Gronow et al., 2001 ), which in turn by binding to gelatin or collagen type IV results in its enzymatic activation without loss of its NH 2 -terminal propeptide (Bannikov et al., 2002) .
Shedding of cell adhesion molecules Cell-cell and cell-ECM adhesions are important in proliferation, costimulatory signals for T-cell activation, wound healing, leukocyte and tumor cell migration. As a consequence of their capacities to shed cell adhesion molecules, TACE and MTl-MMP may affect the adhesive properties of cells and therefore alter their motilities (Black, 2002; Seiki, 2002) . TACE acts as a processing enzyme for L-selectin (Black, 2002) while MTl-MMP cleaves CD44 (Kajita et al., 2001; Seiki, 2002) (Table 3) . L-selectin is expressed by B and T lymphocytes, monocytes, neutrophils, eosinophils and subsets of natural killer cells, and binds endothelial cell surface carbohydrates (Erbe et al., 1993) . CD44, present on most cells and tissues, but absent from platelets and cardiac muscle, binds hyaluronic acid, type I collagen, fibrin and chondroitin sulfate proteoglycans (Isacke and Yarwood, 2002) . The PEX domain of MT1-MMP appears important for the shedding of CD44, stimulation of cell migration and localization to the migration front (Seiki, 2002) . Recent data showed that CD44 can anchor (pro)MMP-9 on the surface of mouse mammary carcinoma and human melanoma cells (Yu and Stamenkovic, 1999) . Such interaction promotes cellmediated collagen IV degradation in vitro and mediates tumor cell invasion (Yu and Stamenkovic, 1999) . Thus, the expression of MT1-MMP on the cell surface, by triggering directly MMP-2, -13 and indirectly CD44-mediated MMP-9 cascades, may be of importance in processes where these proteases are required for angiogenesis. For example, studies show the involvement of MMP-2 in wound healing, MMP-2 and MMP-9 in endometrial blood vessels and placenta microvessels (Bischof et al., 2002; Xu et al., 2002) , MMP-9 in rheumatoid arthritis (Opdenakker and Van Damme, 2002) , MMP-13 in congestive heart failure (Spinale et al., 2000) and MMP-2, MMP-9, MMP-13 in a variety of tumors (Brinckerhoff et al., 2000; McCawley and Matrisian, 2000) .
Do TPs have a place in angiogenesis?
Several in vitro and in vivo assays have been developed to study the distinct events comprising the process of neovascularization, and to provide information about the mechanisms by which a molecule might be exerting its anti-or proangiogenic effects (Moses, 1997) . With regard to TPs, the in vitro assays used are those which measure capillary EC growth (proliferation, DNA synthesis), capillary tube and sprout formation (Moses, 1997) . In vivo asssays included the chorioallantoic membrane (CAM), the (rabbit, mouse, rat) corneal pocket and animal models of hindlimb ischemia (Moses, 1997) . The demonstration of the participation of TPs in angiogenesis has come from studies in which blocking TPs by specific inhibitors or neutralizing antibodies resulted in the perturbation of at least one of these assays. An antiangiogenic effect of TP inhibition was observed for all TPs indicating their positive role in angiogenesis (Table 3 ). In contrast, other lines of evidence have underlined the proangiogenic effect of ACE inhibition (Table 3) .
In vitro assays
APN/CD13 is expressed on the human umbilical vein endothelial cells (HUVECs) of angiogenic, but not normal, vasculature (Pasqualini et al., 2000) . Functional antagonists of APN (bestatin, amastatin, CD13 antibody) abrogate the ability of the HUVECs cultured on Matrigel to organize a capillary network without altering their proliferation rates (Figure 3a ) (Bhagwat et al., 2001; Hashida et al., 2002) . Similarly, the ACE inhibitor perindoprilat inhibits HUVEC tubule formation in Matrigel and VEGF-induced EC migration (Yoshiji et al., 2001 (Yoshiji et al., , 2002a . DPPIV expressed by HUVECs could stimulate angiogenesis in vitro by converting the full length of the vasoconstrictor neuropeptide Y (NPY 1-36 ) to the shorter form NPY 3-36 , which binds to the NPY angiogenic receptors (Chen and Kelly, 2003; Zukowska et al., 2003) .
Pathological angiogenesis is often accompanied by the formation of a fibrinous matrix, which consists of fibrin, collagen fibers and plasma proteins. EC assembly into capillary-like structures within collagen/fibrin gels requires the activity of MT1-MMP (Chan et al., 1998; Lafleur et al., 2002; Koike et al., 2002; Collen et al., 2003) .
In vivo assays
In the corneal pocket assay, the formation of new capillaries is produced by lesions, tumors or angiogenic molecules (such as FGF-2) implanted in pockets created in the central region of the cornea (Diaz-Flores TPs in cell growth and invasion B Bauvois et al., 1994) . The ACE inhibitor, captopril, blocks FGF-2-induced neovascularization in the rat cornea ( Figure 3b ) (Volpert et al., 1996) . Similarly, APN inhibition (by bestatin, actinonin or CD13 antibody) leads to the blockade of hypoxia-induced retinal neovascularization in mice (Pasqualini et al., 2000) . In a mouse corneal assay, FGF-2 is unable to induce an angiogenic response in the MTl-MMP-deficient mice, suggesting that MT1-MMP plays a crucial role in the initial step of angiogenesis (Zhou et al., 2000) . In the CAM assay, the angiogenic response is determined by measuring the number of avian extraembryonic capillary vessels that grow within a matrix polymer (containing an angiogenic molecule) placed on the yolk sac membrane of a 4-day embryo in culture ( Figure 3c ) (Ribatti et al., 2000) . The chick vasculature expresses a phenotype APN/CD13, and subsequent treatment with bestatin or CD13 antibodies inhibits FGF-2-induced angiogenesis (Pasqualini et al., 2000) . Induced hindlimb ischemia is obtained in adult animals (rats, rabbits) by ligation of the femoral artery, and the effect of ischemia is then quantitated by capillary density measurement (Ho¨ckel et al., 1993) . Although the ACE inhibitor captopril blocked microvascular development in hypertensive rats (Wang and Prewitt, 1990) , documented evidence for augmented angiogenesis in ischemic hindlimb -animals treated with other ACE inhibitors (quinaprilat, perindopril, ramipril) is controversial (Fabre et al., 1999; Silvestre et al., 2001; Takeshita et al., 2001; Yoshiji et al., 2002a, b) . The pharmacological effects of ACE inhibition may be in part mediated via inhibition of angiotensin II formation and also via bradykinin accumulation. Both angiotensin II and bradykinin exert proangiogenic activity (Yoshiji et al., 2001) . Thus, the favorable effect of protecting bradykinin from enzymatic cleavage may counterbalance inhibition of angiotensin II generation. In line with this, it has been demonstrated recently that the proangiogenic effect of ACE inhibition in mice with hindlimb ischemia was mediated by the bradykinin B2 receptor pathway (Silvestre et al., 2001) . Thus, caution has to be taken regarding the impact of ACE inhibition on angiogenesis in the context of the dual mode of action of ACE inhibitors (Yoshiji et al., 2002b) .
Conclusions and future prospects
TPs can affect cellular events previously shown to be influenced by secreted proteases (MMPs, uPA and thrombin systems). Through their proteolytic capacities, they influence vascular permeability, cell migration and invasion (and subsequently tumor progression in cancers), growth and secretion of angiogenic molecules. An understanding of the precise molecular mechanisms by which certain TPs may be implicated in angiogenic processes is emerging. A series of targeted TP inhibition and gene knockout studies have started to explain how these TPs could contribute to angiogenic-related pathological processes. In general, TP inhibitors have been shown to inhibit angiogenesis in in vitro and in vivo assays. However, the effect of ACE inhibition on microvasculature remains controversial since ACE inhibitors show proangiogenic activity under certain conditions. It was recently shown that in spontaneously hypertensive rats with defective healing response to ischemia, ACE inhibition by ramipril improves hemodynamic recovery but not microvascular response to ischemia (Emanueli et al., 2002) . Thus, further studies are required to elucidate these issues before clinically prescribing an ACE inhibitor as an antiangiogenic agent. Today, although there are still more questions than answers with regard to TPs and angiogenesis, one can anticipate rapid and substantial progress in the near future. It is likely that additional TPs already known to play roles in distinct pathophysiological contexts (such as neprilysins, seprases or aminopeptidase A) would be involved in key aspects of angiogenesis.
